Voudouragkaki Irini C

2 articles in GJC

Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease-a randomized controlled trial.

Konstas Anastasios-Georgios, Boboridis Konstadinos G, Athanasopoulos Georgios P, Haidich Anna-Bettina, Voudouragkaki Irini C, Pagkalidou Eirini et al.

Eye (Lond)May 20239 citationsRandomized Controlled Trial

Switching to preservative-free glaucoma drops improved ocular surface disease (OSD) and IOP control, with added cyclosporine 0.1% further reversing OSD, benefiting patients on long-term therapy.

Full abstract PubMed

Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.

Konstas Anastasios G P, Quaranta Luciano, Katsanos Andreas, Riva Ivano, Tsai James C, Giannopoulos Theodoros et al.

Br J OphthalmolDec 201352 citationsRandomized Controlled Trial

This study compared preservative-free tafluprost and latanoprost for 24-hour IOP control in glaucoma/OHT. Both achieved similar overall IOP reduction, but tafluprost showed less fluctuation, offering nuanced treatment choices.

Full abstract PubMed

All 2 articles loaded

Global Search

Voudouragkaki Irini C

Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease-a randomized controlled trial.

Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.